Ascentage Pharma has announced that its new drug application (NDA) for lisaftoclax, a Bcl-2 inhibitor, has been accepted for priority review by China's National Medical Products Administration (NMPA). This regulatory milestone positions lisaftoclax to potentially become the first drug of its kind approved in China and only the second worldwide for the treatment of chronic lymphocytic leukemia (CLL).
Addressing Unmet Needs in CLL Treatment
Chronic lymphocytic leukemia is a type of cancer that affects the blood and bone marrow. Lisaftoclax represents a significant advancement in addressing the unmet needs of patients with relapsed or refractory CLL, who often have limited treatment options. The priority review designation by the NMPA underscores the urgent need for innovative therapies in this patient population.
Mechanism of Action
Lisaftoclax functions as a selective inhibitor of Bcl-2, a protein that prevents apoptosis (programmed cell death) in cancer cells. By blocking Bcl-2, lisaftoclax promotes cancer cell death, thereby reducing the tumor burden in CLL patients. This targeted mechanism of action offers a potential advantage over traditional chemotherapy regimens, which can have broader and more toxic effects.
Clinical Significance
The anticipated approval of lisaftoclax in China would provide a valuable new treatment option for CLL patients, particularly those with relapsed or refractory disease. The drug's novel mechanism of action and potential for improved outcomes highlight its clinical significance in the evolving landscape of CLL therapy.
